Author | Ian Flinn, MD | OncLive

Author | Ian Flinn, MD

Articles

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25, 2018

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11, 2018

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL

June 12, 2018

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

February 14, 2018

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

x